H. Lundbeck AS 

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily specializes in therapeutic solutions for psychiatric and neurological disorders across Europe, North America, and other worldwide regions. Among its prominent offerings are Abilify Maintena and Rexulti/Rxulti, prescribed for schizophrenia; Brintellix/Trintellix and Rexulti/Rxulti for the management of depression; Vyepti for the prevention of migraine attacks; and Northera, used to treat symptomatic neurogenic orthostatic hypotension. Lundbeck's diverse product lineup further includes Azilect for Parkinson's disease, Cipralex/Lexapro for depression, Ebixa for Alzheimer's disease, Onfi for Lennox-Gastaut syndrome, Sabril for epilepsy, and Xenazine for chorea associated with Huntington's disease, among others. The company's pharmaceuticals are primarily distributed to pharmaceutical wholesalers, retail pharmacies, and healthcare facilities like hospitals. Demonstrating a commitment to innovation and evidence-based medicine, Lundbeck has forged strategic alliances, including an agreement with Verantos to gather real-world evidence supporting migraine therapies, and a partnership with Rgenta Therapeutics, Inc. Founded in 1915, H. Lundbeck A/S maintains its corporate headquarters in Valby, Denmark.